

## RESEARCH ARTICLE

# Longitudinal changes in blood biomarkers and their ability to predict type 2 diabetes mellitus—The Tromsø study

Giovanni Allaoui<sup>1,2</sup> | Charlotta Rylander<sup>3</sup> | Maria Averina<sup>1,3</sup> | Tom Wilsgaard<sup>3</sup> |  
Ole-Martin Fuskevåg<sup>1</sup> | Vivian Berg<sup>1,2</sup> 

<sup>1</sup>Division of Diagnostic Services,  
Department of Laboratory Medicine,  
University Hospital of North Norway,  
Tromsø, Norway

<sup>2</sup>Department of Medical Biology, Faculty  
of Health Sciences, UiT-The Arctic  
University of Norway, Tromsø, Norway

<sup>3</sup>Department of Community Medicine,  
Faculty of Health Sciences, UiT-The Arctic  
University of Norway, Tromsø, Norway

## Correspondence

Vivian Berg, Department of Medical  
Biology, Faculty of Health Sciences,  
UiT-The Arctic University of Norway, NO-  
9037 Tromsø, Norway.  
Email: vivian.berg@uit.no

## Funding information

This study was financed by the Northern  
Norway Regional Health Authority  
(project number HNF1470-19). The  
funders were not involved in the design of  
the study, collection and interpretation of  
data, or the writing and submission of the  
manuscript

## Abstract

**Introduction:** Identification of individuals at high risk of developing type 2 diabetes mellitus (T2DM) is important for early prevention of the disease. Once T2DM is established, it is difficult to treat and is associated with cardiovascular complications and increased mortality. We aimed to describe pre- and post-diagnostic changes in blood biomarker concentrations over 30 years in individuals with and without T2DM, and to determine the predictive potential of pre-diagnostic blood biomarkers.

**Methods:** This nested case-control study included 234 participants in the Tromsø Study who gave blood samples at five time points between 1986 and 2016: 130 did not develop T2DM and were used as controls; 104 developed T2DM after the third time point and were included as cases. After stratifying by sex, we investigated changes in pre- and post-diagnostic concentrations of lipids, thyroid hormones, HbA<sub>1c</sub>, glucose and gamma-glutamyltransferase (GGT) using linear mixed models. We used logistic regression models and area under the receiver operating characteristic curve (AROC) to assess associations between blood biomarker concentrations and T2DM, as well as the predictive ability of blood biomarkers.

**Results:** Cases and controls experienced different longitudinal changes in lipids, free T<sub>3</sub>, HbA<sub>1c</sub>, glucose, and GGT. The combination of selected blood biomarker concentrations and basic clinical information displayed excellent (AROC 0.78–0.95) predictive ability at all pre-diagnostic time points. A prediction model that included HDL (for women), HbA<sub>1c</sub>, GGT, and basic clinical information demonstrated the strongest discrimination 7 years before diagnosis (AROC 0.95 for women, 0.85 for men).

**Conclusion:** There were clear differences in blood biomarker concentrations between cases and controls throughout the study, and several blood biomarkers were associated with T2DM. Selected blood biomarkers (lipids, HbA<sub>1c</sub>, GGT) in combination with BMI, physical activity, elevated blood pressure, and family history of T2DM had excellent predictive ability 1–7 years before T2DM diagnosis and acceptable predictive ability up to 15 years before diagnosis.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Endocrinology, Diabetes & Metabolism* published by John Wiley & Sons Ltd.

## KEYWORDS

biomarkers, blood test, health service, longitudinal survey, preventive, risk factors, type 2 diabetes mellitus

## 1 | INTRODUCTION

The prevalence of type 2 diabetes mellitus (T2DM) has increased substantially over the past few decades and is one of the most important global health challenges of the 20th century.<sup>1</sup> The disease is characterized by insufficient insulin secretion and/or insulin resistance and established risk factors include among other obesity, sedentary lifestyle, excess dietary intake, and genetic factors.<sup>2</sup> Previous longitudinal studies of repeated pre-diagnostic measurements have demonstrated increases in lipid and glucose concentrations 1.5–20 years before T2DM diagnosis, with steeper increases closer to diagnosis.<sup>3–10</sup> Thus, disruption of metabolic homeostasis involving lipids, thyroid hormones, glucose, and liver enzymes is associated with T2DM.<sup>5,8,9,11–13</sup> However, the sequence of this disruption and its relative contribution to the progression from normal to impaired glucose tolerance, and ultimately to T2DM, remains unknown.<sup>14,15</sup>

Prediabetes (i.e., higher-than-normal blood glucose concentrations) precedes T2DM. Once T2DM has manifested, it is irreversible, difficult to treat, and associated with cardiovascular complications and increased mortality.<sup>16–18</sup> The identification of blood biomarkers and the development of risk score models for prediabetes and T2DM are therefore highly relevant, as they will enable early identification of high-risk individuals. There are currently many risk score models for diabetes (reviewed by Buijsse et al.<sup>19</sup>) most are based on basic clinical information like age, body mass index (BMI), physical activity, blood pressure and genetic predisposition, but some also include blood biomarkers. For instance, the FINDRISC (including basic clinical information as well as daily consumption of vegetables, fruits or berries, and history of high glucose) and the Framingham (including basic clinical information as well as high-density lipoprotein (HDL) and triglycerides) risk scores for diabetes have been shown to successfully identify high-risk individuals 5–7 years before diagnosis.<sup>20,21</sup>

Several studies of risk score models have shown that adding blood biomarkers to basic clinical information improves predictive ability,<sup>4,20,22</sup> especially biomarkers involved in glycaemic processes, uric acid, and lipids. However, most studies on prediction models are based on a single baseline blood sample.<sup>4,23</sup> The Tromsø Study contains blood biomarker concentrations and basic clinical information for up to five time points. Hence, we aimed to describe pre- and post-diagnostic changes in blood biomarker concentrations over 30 years in individuals with and without T2DM, and to determine the predictive potential of pre-diagnostic blood biomarkers.

## 2 | METHODS

### 2.1 | Study population

The Tromsø Study is a population-based health survey carried out in the Tromsø municipality in Northern Norway. The first survey, Tromsø1, was carried out in 1974, and six more surveys followed (Tromsø2–Tromsø7), one about every 6–7 years. During each survey, participants completed questionnaires, underwent a clinical examination and gave a blood sample.<sup>24,25</sup>


The present, longitudinal, nested case–control study includes blood samples collected from the same individuals at five time points: Tromsø3 (1986/87), Tromsø4 (1994/95), Tromsø5 (2001), Tromsø6 (2007/08) and Tromsø7 (2015/16). Hereafter, Tromsø3–Tromsø7 will be referred to as time point 1–5 (T1–T5), where cases developed T2DM after T3. Hence, T1–T3 was defined as the pre-diagnostic time period, whereas T4 and T5 were defined as the post-diagnostic time period.

Initially, all participants with a T2DM diagnosis were recorded in a local diabetes registry between 2000 (T3) and 2006 (T4), and available pre-diagnostic serum samples were eligible for inclusion as cases (76 women, 69 men). We then randomly selected 76 women and 69 men who participated in the same surveys, had serum samples for T1–T3 and had no T2DM diagnosis recorded in a local diabetes registry during the surveys as controls. Of the initial 290 participants, we excluded 29 cases with glycated haemoglobin (HbA<sub>1c</sub>)  $\geq 48$  mmol/mol (6.5%) before or at T3, and seven controls with HbA<sub>1c</sub>  $\geq 48$  mmol/mol (6.5%) at any time point. We also excluded participants who reported using medications that could affect glucose and thyroid hormone concentrations before T3 (8 controls, 2 cases). Thus, the final study population comprised 234 individuals (104 cases, 130 controls). Of these, 88 had blood samples for T1–T3 (38 cases, 50 controls), 45 (21 cases, 24 controls) had samples for T1–T4, 39 (18 cases, 21 controls) for T1–T3 and T5, and 62 (27 cases, 35 controls) had blood samples for T1–T5 (Figure 1). All participants gave informed consent at the time of each survey. The study protocol was approved by the Regional Ethics Committee, REK, nord (REK reference: 2015/1780/REK nord).

### 2.2 | Questionnaires, clinical examination and blood collection

The Tromsø Study questionnaire and measurements have been described in detail elsewhere.<sup>24,25</sup> Briefly, each survey included a

**FIGURE 1** Study flow chart presents the study sample according to participation in three or more surveys, and how many blood samples were analysed for the different biomarkers at each time point (T1–T5). HbA<sub>1c</sub>, Glycated haemoglobin; HDL, High-density lipoprotein; GGT, Gamma-glutamyltransferase; LDL, Low-density lipoprotein; NA, not available; T, Time point; T<sub>3</sub>, Triiodothyronine; T<sub>4</sub>, Thyroxine; T2DM, type 2 diabetes mellitus; TSH, Thyroid-stimulating hormone. The Tromsø Study 1986–2016



<sup>a</sup>TSH analyses were performed at time of blood collection in 1994/1995.

<sup>b</sup>All analyses were performed at the time of blood collection at the respective survey.

questionnaire that collected information on lifestyle habits, self-reported diseases such as diabetes, family history of diseases including T2DM, parity and breastfeeding. A clinical examination was also conducted at each survey and included measurements of weight, height, waist circumference and blood pressure, among others, and the collection of non-fasting blood samples. Several analyses were performed in fresh blood samples; serum samples were frozen and stored for later use.<sup>25</sup>

### 2.3 | Laboratory analyses and availability of blood biomarkers

Serum samples were thawed and analysed for triglycerides, total cholesterol, low-density lipoprotein (LDL), HDL, free triiodothyronine (T<sub>3</sub>), free thyroxine (T<sub>4</sub>) and thyroid-stimulating hormone (TSH), but serum samples from T2 were insufficient for analyses of free T<sub>3</sub>, free T<sub>4</sub> and TSH. Data from previous analyses carried out at the time of blood collection were available for TSH (T2), HbA<sub>1c</sub> (T2–T5), glucose (T2–T5) and gamma-glutamyltransferase (GGT; T1–T2, T4). Included blood biomarkers varied at each time point (Figure 1). All analyses were performed at the University Hospital of North Norway, Department of Laboratory Medicine, using routine, established procedures. Serum concentrations of triglycerides, total cholesterol, LDL, HDL, free T<sub>3</sub>, free T<sub>4</sub>, TSH, glucose and GGT were determined using the Cobas<sup>®</sup> 8000 platform (Roche Diagnostics, Switzerland). Until 2006, GGT was analysed at 37°C in a Hitachi 737 Automatic Analyser using commercial kits (Boehringer Mannheim, Germany) according to the recommendations of the Scandinavian Enzymes Committee.<sup>26</sup> HbA<sub>1c</sub> was determined by high-performance liquid chromatography using an automated analyser (Variant II,

Bio-Rad Laboratories). Laboratory personnel were blinded to the sample order and survey number. The laboratory is certified according to the ISO 151189 standard.<sup>27</sup> Quality controls are run routinely, at three different concentrations every day, and the laboratory also participates in the external quality assessment program, Lab Quality.<sup>28</sup> Total lipids (g/L) were calculated according to the formula<sup>29</sup>:

$$\text{Total lipids} = 2.27 \times \text{total cholesterol} + \text{triglycerides} + 0.623$$

### 2.4 | Statistical analyses

Blood biomarker concentrations and demographic variables are reported as means with standard deviations, medians with 5 and 95 percentiles, and/or frequencies with percentages. Sample characteristics were compared between cases and controls at each time point using unpaired two-sample t-tests for continuous variables and Pearson's chi-squared for categorical variables.

Linear mixed effects models were used to explore the rate and significance of changes in blood biomarker concentrations at T1–T5, between and within cases and controls, after adjusting for the following established risk factors for T2DM<sup>30</sup>: age (continuous), BMI (continuous), physical activity (active:  $\geq 3$  h/week of light activity and/or  $\geq 1$  h hard exercise/week or sedentary:  $< 3$  h/week of activity that provoked transpiration or no activity), elevated blood pressure (systolic blood pressure  $\geq 130$ , diastolic blood pressure  $\geq 85$ , and/or if the subject was taking blood pressure medication, yes/no) and family history of T2DM (siblings and/or parents with T2DM, yes/no). Blood biomarkers were used as dependent variables (continuous), whereas T2DM status, established risk factors and indicator variables of time with interaction terms with T2DM status were used as independent

TABLE 1 Characteristics of the study sample across five surveys of the Tromsø Study 1986–2016

			Pre-diagnostic time points			
			T1 (1986/87)		T2 (1994/95)	
			Mean (SD)	ΔMean case-control (95% CI)	Mean (SD)	ΔMean case-control (95% CI)
Age (years)	Women <sup>a</sup>	Case	45.3 (6.31)	1.46 (-1.48, 4.39)	53.3 (6.31)	1.46 (-1.48, 4.39)
		Control	43.9 (8.98)		51.9 (8.98)	
	Men <sup>b</sup>	Case	48.4 (8.61)	2.05 (-1.57, 5.66)	56.4 (8.61)	2.05 (-1.57, 5.66)
		Control	46.4 (10.7)		54.4 (10.7)	
Parity (n)	Women <sup>a</sup>	Case	2.66 (1.56)	0.24 (-0.35, 0.83)	2.85 (1.38)	0.34 (-0.21, 0.89)
		Control	2.42 (1.56)		2.51 (1.45)	
Breastfeeding (months)	Women <sup>a</sup>	Case	NA	NA	13.5 (11.5)	-1.52 (-6.22, 3.19)
		Control	NA	NA	15.0 (10.8)	
Weight (kg)	Women <sup>a</sup>	Case	71.9 (12.1)	8.41 (4.39, 12.4)***	77.5 (13.8)	10.7 (6.06, 15.4)***
		Control	63.4 (10.0)		66.7 (11.8)	
	Men <sup>b</sup>	Case	85.1 (12.9)	6.94 (2.81, 11.1)**	88.5 (13.3)	7.41 (3.07, 11.8)**
		Control	78.2 (9.24)		81.1 (10.2)	
BMI (kg/m <sup>2</sup> )	Women <sup>a</sup>	Case	27.5 (4.38)	3.63 (2.14, 5.13)***	29.8 (5.13)	4.54 (2.74, 6.34)***
		Control	23.9 (3.83)		25.3 (4.72)	
	Men <sup>b</sup>	Case	27.5 (3.55)	2.94 (1.77, 4.10)***	28.6 (3.49)	3.03 (1.83, 4.24)***
		Control	24.6 (2.73)		25.6 (3.03)	
Waist circumference (cm)	Women <sup>a</sup>	Case	NA	NA	93.0 (11.4)	11.8 (6.39, 17.3)***
		Control	NA	NA	81.2 (9.95)	
	Men <sup>b</sup>	Case	NA	NA	101 (7.89)	7.28 (4.19, 10.4)***
		Control	NA	NA	93.7 (7.37)	
Diastolic blood pressure (mmHg)	Women <sup>a</sup>	Case	81.3 (10.3)	6.14 (2.31, 9.97)**	83.9 (12.2)	4.93 (0.53, 9.33)*
		Control	75.1 (10.5)		79.0 (11.8)	1.90 (-2.21, 6.01)
	Men <sup>b</sup>	Case	85.6 (9.67)	3.36 (-0.32, 7.04)	85.7 (11.2)	
		Control	82.2 (10.2)		83.8 (11.1)	
Systolic blood pressure (mmHg)	Women <sup>a</sup>	Case	131 (16.0)	7.49 (1.54, 13.4)*	142 (20.0)	7.36 (-0.09, 14.8)
		Control	124 (16.3)		135 (20.5)	
	Men <sup>b</sup>	Case	139 (14.2)	3.84 (-1.75, 9.43)	146 (19.8)	6.18 (-0.69, 13.0)
		Control	135 (15.9)		139 (17.4)	

Abbreviations: BMI, body mass index; T, time point.

<sup>a</sup>Fifty cases and 69 controls at T1–T3, 44 cases and 53 controls at T4, 26 cases and 40 controls at T5.

<sup>b</sup>Fifty-four cases and 61 controls at T1–T3, 38 cases and 38 controls at T4, 20 cases and 28 controls at T5.

\* $p < .05$ ; \*\* $p < .01$ ; \*\*\* $p < .001$ .

variables. A random intercept at the participant level was included to control for repeated measurements over time, with an unstructured variance and covariance correlation structure for within-group errors.

We assessed the associations between pre-diagnostic blood biomarker concentrations and T2DM. Logistic regression analyses were used to estimate odds ratios of T2DM for each time point separately. We fitted two models per blood biomarker: the first included blood biomarker concentration as a continuous, independent variable; in the second model, the blood biomarker was dichotomized according to clinical guidelines and concentrations associated with an increased risk of T2DM. Both models were adjusted for established


risk factors, and odds ratios were estimated either per 1-unit increase in blood biomarker concentration or above versus below the defined clinical cut-off values: triglycerides  $>1.70$  g/L, HDL  $<1.30$  mmol/L for women and  $<1.03$  for men,<sup>30</sup> total cholesterol  $>5.00$  mmol/L, LDL  $>3.00$  mmol/L<sup>31</sup> and HbA<sub>1c</sub>  $>39.0$  mmol/mol (5.7%).<sup>18</sup> Cut-offs for blood biomarkers with no clinical guidelines were based on a receiver operating characteristics curve (ROC) analysis in pre-diagnostic samples, which yielded the highest discrimination between cases and controls, and were as follows: total lipids  $>7.40$  g/L for women (62.7% sensitivity, 63.3% specificity) and  $>7.59$  for men (61.5% sensitivity, 61.5% specificity), free T<sub>3</sub>  $>5.20$  pmol/L for women (33.0% sensitivity, 80.4% specificity) and  $>5.12$  for

T3 (2001)		Post-diagnostic time points			
		T4 (2007/08)		T5 (2015/16)	
Mean (SD)	ΔMean case-control (95% CI)	Mean (SD)	ΔMean case-control (95% CI)	Mean (SD)	ΔMean case-control (95% CI)
60.3 (6.31)	1.46 (-1.48, 4.39)	65.9 (6.39)	0.26 (-2.66, 3.18)	73.4 (6.07)	2.92 (-1.34, 7.19)
58.9 (8.98)		65.6 (7.83)		70.5 (9.71)	
63.4 (8.61)	2.05 (-1.57, 5.66)	68.5 (6.97)	1.61 (-2.37, 5.58)	72.6 (7.82)	2.34 (-3.43, 8.10)
61.4 (10.7)		66.9 (10.2)		70.2 (11.0)	
2.81 (1.54)	0.23 (-0.32, 0.79)	2.72 (1.45)	-0.09 (-0.70, 0.52)	2.62 (1.36)	-0.11 (-0.94, 0.73)
2.58 (1.45)		2.81 (1.52)		2.73 (1.83)	
15.1 (12.2)	-0.71 (-5.59, 4.18)	14.7 (13.5)	0.22 (-8.41, 3.73)	11.4 (8.57)	-8.70 (-15.3, -2.10) <sup>†</sup>
15.8 (11.5)		17.0 (12.4)		20.1 (13.5)	
81.9 (15.0)	12.2 (7.23, 17.2) <sup>***</sup>	81.7 (15.8)	12.6 (6.70, 18.5) <sup>***</sup>	81.6 (18.3)	11.8 (3.42, 20.2) <sup>**</sup>
69.7 (12.3)		69.1 (13.4)		69.8 (15.1)	
91.4 (14.0)	7.72 (2.98, 12.5) <sup>**</sup>	90.4 (12.0)	5.69 (0.41, 11.0) <sup>†</sup>	90.2 (14.5)	4.18 (-3.42, 11.8)
83.7 (11.6)		84.7 (10.9)		86.0 (11.7)	
31.8 (5.90)	5.22 (3.29, 7.15) <sup>***</sup>	31.8 (6.34)	5.05 (2.72, 7.37) <sup>***</sup>	31.5 (7.28)	4.64 (1.39, 7.89) <sup>**</sup>
26.5 (4.72)		26.7 (5.19)		26.9 (5.87)	
29.8 (3.58)	3.29 (1.99, 4.59) <sup>***</sup>	29.4 (3.45)	2.50 (0.95, 4.05) <sup>**</sup>	29.6 (3.79)	2.32 (0.19, 4.45) <sup>†</sup>
26.6 (3.46)		26.9 (3.29)		27.2 (3.49)	
96.1 (12.4)	12.0 (7.30, 16.8) <sup>***</sup>	103 (12.9)	12.7 (7.40, 17.9) <sup>***</sup>	105 (14.8)	14.7 (7.55, 21.8) <sup>***</sup>
84.1 (13.2)		90.1 (12.5)		90.0 (13.6)	
104 (9.43)	7.80 (4.23, 11.4) <sup>***</sup>	106 (8.66)	5.02 (0.81, 9.23) <sup>†</sup>	108 (12.5)	5.85 (-0.73, 12.4)
95.8 (9.87)		101 (9.36)		102 (10.1)	
85.1 (14.7)	6.97 (2.16, 11.8) <sup>**</sup>	79.2 (10.2)	2.37 (-1.86, 6.61)	71.0 (10.4)	-3.91 (-9.61, 1.80)
78.2 (11.7)		76.8 (10.5)		74.9 (11.9)	
83.2 (11.6)	-0.74 (-5.57, 4.09)	78.2 (12.0)	-4.22 (-9.33, 0.89)	72.8 (9.81)	-7.16 (-13.3, -1.05) <sup>†</sup>
84.0 (14.2)		82.4 (10.1)		80.0 (10.8)	
146 (21.0)	11.3 (3.34, 19.2) <sup>**</sup>	154 (25.4)	6.39 (-4.22, 16.9)	140 (25.4)	0.96 (-11.5, 13.4)
135 (22.1)	1.26 (-6.40, 8.93)	147 (26.5)		139 (24.4)	
143 (20.5)		144 (24.4)	2.19 (-8.44, 12.8)	132 (18.1)	-7.58 (-18.7, 3.52)
142 (20.6)		142 (21.6)		139 (19.4)	

men (54.6% sensitivity, 59.0% specificity), free  $T_4$  <14.8 pmol/l for women (26.0% sensitivity, 53.6% specificity) and <14.0 for men (50.9% sensitivity, 34.7% specificity), TSH >1.92 mIU/L for women (47.0% sensitivity, 60.9 specificity) and >1.85 for men (61.1% sensitivity, 44.3% specificity), glucose >5.78 mmol/L for women (38.5% sensitivity, 91.3% specificity) and >5.59 for men (41.2% sensitivity, 77.3% specificity), and GGT >20.0 U/L for women (46.0% sensitivity, 83.9% specificity) and >25.0 for men (63.0% sensitivity, 68.9% specificity).

We assessed the following models: (1) a logistic regression model for established risk factors (age, BMI, physical activity, elevated blood pressure, family history of T2DM); (2) a blood biomarker

model based on the significant blood biomarkers ( $p < .05$ ) from the univariable unadjusted models, which were further reduced by a backwards selection process with best model fit as the selection criteria; and (3) a combined model including both established risk factors and blood biomarkers, using the same selection process as for the blood biomarker model. Model fit was assessed by Akaike's information criterion (AIC). Model discrimination was used to determine predictive value, assessed by area under the receiver operating characteristics (AROC). As per Hosmer and Lemeshow, an AROC of 0.50 indicates no discrimination, 0.50–0.70 poor discrimination, 0.70–0.80 acceptable discrimination, 0.80–0.90 excellent discrimination and  $\geq 0.90$  outstanding discrimination.<sup>32</sup>



**FIGURE 2** Pre- and post-diagnostic blood biomarker concentrations across surveys in female cases (red) and controls (blue) and male cases (purple) and controls (orange). Sample number for females were: 50 cases and 69 controls at T1–T3, 44 cases and 53 controls at T4, 26 cases and 40 controls at T5; and for males: 54 cases and 61 controls at T1–T3, 38 cases and 38 controls at T4, 20 cases and 28 controls at T5. HbA<sub>1c</sub>, Glycated haemoglobin; HDL, High-density lipoprotein; GGT, Gamma-glutamyltransferase; LDL, Low-density lipoprotein; T, Time point; T<sub>3</sub>, Triiodothyronine; T<sub>4</sub>, Thyroxine; T2DM, type 2 diabetes mellitus; TSH, Thyroid-stimulating hormone. The Tromsø Study 1986–2016

Statistical analyses were performed in STATA (v. 17, StataCorp LLC, 4905 Lakeway Drive, College Station). All statistical analyses were stratified by sex, *p* values were two-sided, and a 5% level of significance was used.

### 3 | RESULTS


#### 3.1 | Study sample characteristics

Type 2 diabetes mellitus cases and controls were similar in age, whereas cases were heavier, had higher BMI, and larger waist circumference (except men at T5) at all time points (Table 1). At pre-diagnostic time points, female cases had significantly higher blood pressure than controls, except for systolic blood pressure at T2. We observed no significant differences in blood pressure for males, except at T5, when cases had significantly lower diastolic blood pressure. In general, there were no differences in alcohol consumption or

physical activity between cases and controls (Table S1), and no significant differences in parity or duration of breastfeeding between female cases and controls (Table 1). Female cases reported a family history of T2DM more frequently than female controls (Table S1).

Female cases had significantly higher triglyceride, HbA<sub>1c</sub>, and glucose concentrations, and lower HDL concentrations than controls at all time points. Female cases also had significantly higher pre-diagnostic total lipids, total cholesterol (T2), free T<sub>3</sub> (T3) and GGT (T1–T2) concentrations than controls (Figure 2 and Table S2). However, post-diagnostic total cholesterol and LDL concentrations were significantly lower in cases than controls. Similarly, male cases had higher HbA<sub>1c</sub> and glucose (except at T2) concentrations than controls at all time points. Further, male cases had higher pre-diagnostic total lipid (T1), triglyceride (T1 and T3), total cholesterol (T1), and GGT (T2) concentrations, and lower HDL concentrations (T3) than controls. Finally, post-diagnostic total cholesterol (T4), free T<sub>3</sub> (T5) and TSH (T5) concentrations were significantly higher in cases than controls.

## Women



**FIGURE 3** Estimated mean pre- and post-diagnostic blood biomarker concentrations (y-axis) across up to five time points (x-axis) for female cases (red) and controls (blue). Sample numbers: 50 cases and 69 controls at T1–T3, 44 cases and 53 controls at T4, 26 cases and 40 controls at T5. Models are adjusted for age, BMI, physical activity, elevated blood pressure and family history of type 2 diabetes. Dots represent mean concentrations and whiskers the 95% CI around the mean. HbA<sub>1c</sub>, Glycated haemoglobin; HDL, High-density lipoprotein; GGT, Gamma-glutamyltransferase; LDL, Low-density lipoprotein; NA, not available; T, Time point; T<sub>3</sub>, Triiodothyronine; T<sub>4</sub>, Thyroxine; T2DM, type 2 diabetes mellitus; TSH, Thyroid-stimulating hormone. The Tromsø Study 1986–2016

### 3.2 | Longitudinal changes in blood biomarkers

After adjusting for age, BMI, physical activity, elevated blood pressure and family history of T2DM, female cases experienced a significantly larger increase in pre-diagnostic free T<sub>3</sub> (T1–T3), HbA<sub>1c</sub> (T2–T3) and GGT (T1–T2) concentrations compared to controls (Figure 3 and Table S3). Further, there was a significantly larger increase in HbA<sub>1c</sub> concentrations, and a larger decrease in total cholesterol, LDL and free T<sub>3</sub> concentrations in cases compared to controls from T3–T5.

Male cases experienced a significantly larger decrease in pre-diagnostic total lipid, total cholesterol, and LDL concentrations compared to controls, whereas significantly larger increases in HbA<sub>1c</sub> and glucose concentrations were observed from T2–T3 in cases (Figure 4 and Table S3). Further, there was a significantly larger increase in post-diagnostic HbA<sub>1c</sub> and HDL concentrations, and a larger decrease in free T<sub>3</sub> concentrations in cases compared to controls from T3–T5.


### 3.3 | Associations between pre-diagnostic blood biomarker concentrations and T2DM

In women, pre-diagnostic concentrations above the predefined cut-offs for HDL (T1) and free T<sub>4</sub> (T3) were inversely associated with T2DM, while total lipids and free T<sub>3</sub> (T3); triglycerides, HbA<sub>1c</sub> and glucose (T2 and T3); and GGT (T2) were positively associated with T2DM after adjusting for established risk factors (Table S4). Further, HDL (T3), HbA<sub>1c</sub> (T2 and T3), GGT (T2), total lipids (T3), triglycerides (T3) and free T<sub>3</sub> (T3) were associated with T2DM in a linear, dose-response manner. For men, concentrations above the predefined cut-offs for HbA<sub>1c</sub> (T2 and T3), GGT (T2), total lipids, free T<sub>3</sub> and non-fasting glucose (T3) were positively associated with T2DM (Table S5). HbA<sub>1c</sub> and glucose (T3) displayed a linear, dose-response relationship with T2DM.

At T1, the established risk factors model showed a higher predictive ability than the blood biomarker model for both men and women, while at T2 and T3, the blood biomarker model performed



## Men



**FIGURE 4** Estimated mean pre- and post-diagnostic blood biomarker concentrations (y-axis) across up to five time points (x-axis) for male cases (red) and controls (blue). Sample numbers: 54 cases and 61 controls at T1–T3, 38 cases and 38 controls at T4, 20 cases and 28 controls at T5. Models are adjusted for age, BMI, physical activity, elevated blood pressure, and family history of type 2 diabetes. Dots represent mean concentrations and whiskers the 95% CI around the mean. HbA<sub>1c</sub>, Glycated haemoglobin; HDL, High-density lipoprotein; GGT, Gamma-glutamyltransferase; LDL, Low-density lipoprotein; NA, not available; T, Time point; T<sub>3</sub>, Triiodothyronine; T<sub>4</sub>, Thyroxine; T2DM, type 2 diabetes mellitus; TSH, Thyroid-stimulating hormone. The Tromsø Study 1986–2016

better (Tables 2 and 3). However, the combined model had increased predictive ability at every pre-diagnostic time point. The strongest discrimination between cases and controls was observed at T2 (95% for women and 85% for men), when the models for men and women were similar but not identical, as HDL was included for women only. Excluding HDL reduced discrimination among women to 94%, with a small loss of model fit (AIC 77.1 vs. 76.4).

## 4 | DISCUSSION

In this nested case–control study, we observed differences between cases and controls in total lipids, triglycerides, total cholesterol, HbA<sub>1c</sub>, glucose and GGT that were present 15 years before T2DM diagnosis in cases. The model including established risk factors (age, BMI, physical activity, blood pressure and family history of T2DM) was sufficient to acceptably discriminate between cases and controls as early as 15 years before diagnosis (AROC: 0.73 for men and 0.76 for women), but discrimination increased in the combined model, which added blood biomarkers (0.78 and 0.79, respectively).

The blood biomarker model displayed better predictive ability than the established risk factor model 7 years before diagnosis in cases (T2, AROC: 0.78 versus 0.73 in men and 0.88 versus 0.83 in women), but the combined model gave excellent predictive ability for men (AROC: 0.85) and outstanding predictive ability for women (AROC: 0.95). These findings suggest that several biomarkers of metabolic homeostasis, alone or combined with basic clinical information, can be used to predict T2DM up to 7 years before diagnosis. These blood biomarkers can be analysed easily and cost-effectively and provide objective measures. This approach could help identify high-risk individuals early, allowing preventive interventions to be implemented.

Our results showed that, regardless of the pre-diagnostic time point, a prediction model combining easily obtainable blood biomarkers and basic clinical information provided excellent predictive ability, even when different biomarkers are included. Using repeated measurements, we revealed that blood biomarkers have the potential to consistently predict disease 15 years before diagnosis. Our results are in agreement with other studies that used a single blood sample collected 5–10 years before T2DM diagnosis.<sup>3,20–22,33,34</sup> Although these studies included different basic



TABLE 2 Multivariable prediction of type 2 diabetes according to established risk factors and blood biomarkers across pre-diagnostic time points in women. The Tromsø Study 1986–2016

T1 (1986/87)	T2 (1994/95)		T3 (2001)	
	OR (95% CI)	AROC	OR (95% CI)	AROC
<b>Established risk factors<sup>a</sup></b>				
BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	3.19 (1.23, 8.27)	0.76	BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	5.60 (1.70, 18.5)
BMI $\geq 30$ (kg/m <sup>2</sup> )	6.26 (1.86, 21.0)		BMI $\geq 30$ (kg/m <sup>2</sup> )	15.3 (3.98, 58.7)
Physical activity (active)	1.20 (0.43, 3.34)		Physical activity (active)	0.36 (0.15, 0.90)
Elevated blood pressure (yes)	2.19 (0.91, 5.27)		Elevated blood pressure (yes)	1.34 (0.48, 3.73)
Family history of T2DM (yes)	4.21 (1.28, 13.8)		Family history of T2DM (yes)	7.77 (2.40, 25.2)
<b>Blood biomarker<sup>b</sup></b>				
HDL $\geq 1.29$ (mmol/L)	0.36 (0.16, 0.80)	0.66	Total lipids $\geq 7.40$ (g/L)	3.88 (1.21, 12.5)
GGT $\geq 20.0$ (U/L)	3.31 (1.12, 9.73)		HDL $\geq 1.29$ (mmol/l)	0.47 (0.15, 1.47)
			HbA <sub>1c</sub> $\geq 39.0$ (mmol/mol)	15.2 (3.28, 70.8)
			GGT $\geq 20.0$ (U/L)	18.3 (5.03, 66.4)
<b>Combined model<sup>a,b</sup></b>				
HDL $\geq 1.29$ (mmol/L)	0.39 (0.16, 0.96)	0.79	HDL $\geq 1.29$ (mmol/L)	0.29 (0.06, 1.35)
GGT $\geq 20.0$ (U/L)	2.70 (0.81, 9.03)		HbA <sub>1c</sub> $\geq 39.0$ (mmol/mol)	39.7 (3.65, 432)
BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	3.06 (1.13, 8.25)		GGT $\geq 20.0$ (U/l)	24.2 (3.65, 143)
BMI $\geq 30$ (kg/m <sup>2</sup> )	4.52 (1.24, 16.5)		BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	11.4 (1.63, 79.8)
Physical activity (active)	1.28 (0.43, 3.75)		BMI $\geq 30$ (kg/m <sup>2</sup> )	16.9 (2.00, 142)
Elevated blood pressure (yes)	2.12 (0.85, 5.27)		Physical activity (active)	0.19 (0.04, 0.85)
Family history of T2DM (yes)	3.91 (1.16, 13.2)		Elevated blood pressure (yes)	0.92 (0.15, 5.59)
			Family history of T2DM (yes)	28.6 (3.66, 224)
			Family history of T2DM (yes)	2.25 (0.54, 9.36)
			Family history of T2DM (yes)	2.25 (0.54, 9.36)

Abbreviations: AROC, Area under the receiver operating characteristic curve; BMI, Body mass index; GGT, Gamma-glutamyltransferase; HbA<sub>1c</sub>, Glycated haemoglobin; HDL, High-density lipoprotein; T, Time point; T2DM, type 2 diabetes mellitus; T<sub>3</sub>, Triiodothyronine; T<sub>4</sub>, Thyroxine.

<sup>a</sup>Models were adjusted for age.

<sup>b</sup>Models were selected with backwards selection process according to best model fit.

TABLE 3 Multivariable prediction of type 2 diabetes according to established risk factors and blood biomarkers across pre-diagnostic time points in men. The Tromsø Study 1986–2016

	T1 (1986/87)		T2 (1994/95)		T3 (2001)	
	OR (95%-CI)	AROC	OR (95%-CI)	AROC	OR (95%-CI)	AROC
<b>Established risk factors<sup>a</sup></b>						
BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	5.75 (2.31, 14.3)	0.73	BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	0.73	BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	0.71
BMI $\geq 0$ (kg/m <sup>2</sup> )	8.02 (2.03, 31.7)		BMI $\geq 30$ (kg/m <sup>2</sup> )	18.5 (4.34, 78.5)	BMI $\geq 30$ (kg/m <sup>2</sup> )	13.6 (3.25, 56.5)
Physical activity (active)	0.71 (0.23, 2.18)		Physical activity (active)	0.92 (0.36, 2.35)	Physical activity (active)	1.15 (0.43, 3.06)
Elevated blood pressure (yes)	1.29 (0.50, 3.29)		Elevated blood pressure (yes)	0.96 (0.35, 2.62)	Elevated blood pressure (yes)	0.57 (0.19, 1.66)
Family history of T2DM (yes)	1.47 (0.51, 4.25)		Family history of T2DM (yes)	1.09 (0.41, 2.88)	Family history of T2DM (yes)	1.10 (0.44, 2.77)
<b>Blood biomarker<sup>b</sup></b>						
Total lipids $\geq 7.59$ (g/L)	2.51 (1.07, 5.89)	0.72	HbA <sub>1c</sub> $\geq 39.0$ (mmol/mol)	0.78	Triglycerides $\geq 1.70$ (mmol/l)	0.79
Triglycerides $\geq 1.70$ (mmol/l)	1.76 (0.75, 4.12)		GGT $\geq 25$ (U/L)	14.4 (3.88, 53.1)	HbA <sub>1c</sub> $\geq 39.0$ (mmol/mol)	5.39 (2.11, 13.8)
GGT $\geq 25$ (U/L)	2.91 (1.25, 6.75)				Glucose $\geq 5.59$ (mmol/L)	3.24 (1.22, 8.59)
<b>Combined model<sup>ab</sup></b>						
Total lipids $\geq 7.59$ (g/L)	2.04 (0.81, 5.12)	0.78	HbA <sub>1c</sub> $\geq 39.0$ (mmol/mol)	0.85	Triglycerides $\geq 1.70$ (mmol/l)	0.84
GGT $\geq 25$ (U/l)	2.26 (0.89, 5.74)		GGT $\geq 25$ (U/l)	11.6 (2.61, 51.6)	HbA <sub>1c</sub> $\geq 39.0$ (mmol/mol)	8.50 (2.59, 27.9)
BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	3.89 (1.47, 10.3)		BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	2.08 (0.55, 7.77)	Glucose $\geq 5.59$ (mmol/L)	3.17 (1.02, 9.81)
BMI $\geq 30$ (kg/m <sup>2</sup> )	3.96 (0.88, 17.7)		BMI $\geq 30$ (kg/m <sup>2</sup> )	20.0 (1.61, 248)	BMI $\geq 25 < 30$ (kg/m <sup>2</sup> )	5.88 (1.25, 27.6)
Physical activity (active)	0.72 (0.23, 2.28)		Physical activity (active)	2.23 (0.64, 7.81)	BMI $\geq 30$ (kg/m <sup>2</sup> )	14.9 (2.47, 89.7)
Elevated blood pressure (yes)	1.28 (0.49, 3.37)		Elevated blood pressure (yes)	0.55 (0.14, 2.19)	Physical activity (active)	1.26 (0.34, 4.64)
Family history of T2DM (yes)	1.64 (0.56, 4.83)		Family history of T2DM (yes)	1.25 (0.34, 4.65)	Elevated blood pressure (yes)	0.49 (0.14, 1.73)
					Family history of T2DM (yes)	1.44 (0.40, 5.25)

Abbreviations: AROC, Area under the receiver operating characteristic curve; BMI, Body mass index; GGT, Gamma-glutamyltransferase; HbA<sub>1c</sub>, Glycated haemoglobin; T, Time point; T2DM, type 2 diabetes mellitus.

<sup>a</sup>Models were adjusted for age.

<sup>b</sup>Models were selected with backwards selection process according to best model fit.

clinical information, and sometimes different blood biomarkers, they all showed excellent discrimination (AROC: 0.78–0.90). They also displayed similar predictive abilities, although their biomarkers were different from ours, perhaps because their biomarkers were also related to prediabetic metabolic disturbances. For example, the prediction model proposed by the Framingham offspring study used personal information (age, sex, history of T2DM, BMI), blood pressure, HDL, triglycerides and fasting glucose and had excellent predictive ability (AROC: 0.85) 7 years before diagnosis.<sup>20</sup> Our prediction model for women at T2 (also 7 years before diagnosis) was very similar (e.g., personal information, blood pressure, total lipids, triglycerides and HDL), but we included GGT and HbA<sub>1c</sub>, as fasting blood glucose was not available. As postprandial hyperglycaemia is more common in individuals with prediabetes,<sup>35,36</sup> fasting blood glucose may not identify disturbances in glucose homeostasis as well as HbA<sub>1c</sub>,<sup>37</sup> which may also explain the higher predictive ability of our models compared to the Framingham model. Further, our results are based on non-fasting blood samples, underlining the predictive value of non-fasting biomarkers, which would alleviate some of the restrictions of risk models based on fasting blood samples. Our results also complement studies that included repeated measurements collected from patient's healthcare records in models for predicting T2DM. The studies by Paprott et al.<sup>38</sup> and Pimentel et al.<sup>39</sup> concluded that risk factors such as lifestyle habits, BMI/waist circumference, hypertension and family history of diabetes, as well as temporal changes in these risk factors, successfully predicted future T2DM. The studies by Gurka et al.<sup>40</sup> and Bernardini et al.<sup>41</sup> observed that concentrations and temporal changes in concentrations of triglycerides, HDL, LDL, GGT and urea, strengthened their prediction models.

In the present study, all prediction models performed better in women than in men. Specifically, we observed stronger associations between lipids (total lipids, triglycerides and HDL), free T<sub>3</sub>, free T<sub>4</sub>, HbA<sub>1c</sub>, glucose and T2DM in women than men. Several other studies (reviewed by Kautzky-Willer et al.<sup>42</sup>) demonstrated stronger associations between lipids and incident T2DM in women than men, possibly due to sex differences in fat deposition.<sup>42</sup> Njølstad et al.<sup>43</sup> also observed stronger associations between HDL, triglycerides, random glucose and T2DM in women than men in the Finnmark Study; BMI was a more important risk factor for men.

Many blood biomarkers were significant predictors of T2DM in our study; however, discrimination and model fit were not compromised even after several biomarkers were excluded from the models. This may be due to the very strong predictive abilities of some blood biomarkers. For example, at T2, HDL was significantly associated with T2DM among women after adjusting for established risk factors, but discrimination and model fit did not improve significantly in a model that included only HbA<sub>1c</sub>, GGT and established risk factors. Unfortunately, we did not have GGT and HbA<sub>1c</sub> at every pre-diagnostic time point and could not include them together at T1 and T3. However, we hypothesize that, had they been available, their combined inclusion would have improved the model discrimination at these time points as well. This is in line with previous findings

that HbA<sub>1c</sub> and GGT were on par with or better than a combination of other blood lipids and/or glucose measurements and significantly improved discrimination beyond established risk factors.<sup>3,34</sup> As such, for clinical purposes, our study showed that the inclusion of HbA<sub>1c</sub>, GGT and established risk factors would result in identical prediction models for men and women at all pre-diagnostic time points with excellent predictive ability.

Already at T2, HbA<sub>1c</sub> concentrations were significantly higher in cases (~37 mmol/mol, 5.5%) than controls (~35 mmol/mol, 5.4%), though they were still within normal limits (42–47 mmol/mol, 6.0–6.4%) according to the International Expert Committee.<sup>44</sup> However, our results suggest that a lower HbA<sub>1c</sub> threshold for risk assessment, one more in line with that recommended by the American Diabetes Association, may be warranted, as it would enable earlier identification of high-risk subjects. Our results are in line with studies on HbA<sub>1c</sub> trajectories, which showed similar differences between cases and controls up to 10 years before diagnosis (cases: 37.0–40.0 mmol/mol, 5.5–5.8%; controls: 33.0–35.5 mmol/mol, 5.2–5.4%).<sup>45,46</sup>

We observed that cases had higher average GGT concentrations than controls and that men generally had higher concentrations than women. However, concentrations varied within the normal range of 10–75 U/l for women and 15–115 U/l for men.<sup>31</sup> This is in line with previous studies investigating liver biomarkers in relation to T2DM, which showed significantly higher GGT concentrations in cases than controls, and in men than women, though they remained within normal limits.<sup>5,47,48</sup> GGT has been identified as an independent risk factor for T2DM and is also linked to hepatic steatosis, which in turn is associated with obesity,<sup>49</sup> clearly emphasizing the potential of GGT as a predictive biomarker for T2DM.

Total cholesterol and LDL concentrations decreased in both cases and controls throughout the study period. A general decrease in cholesterol concentrations in the Tromsø Study from 1979 to 2016 was previously reported for both men and women.<sup>50</sup> The authors hypothesized that this was due to changes in cholesterol-associated lifestyle factors in the Norwegian population, such as a general increase in physical activity, and decreased smoking and consumption of trans fats. In our study, the steeper post-diagnostic decrease in cholesterol concentrations among cases may be explained by targeted lifestyle changes following the diagnosis, as individuals with T2DM have been shown to improve their lipid concentrations after diagnosis.<sup>51</sup> The decrease may also be attributed to the use of cholesterol-lowering drugs, as cardiovascular diseases are associated with T2DM. In our study, 43%–70% of cases and 5%–24% of controls reported using lipid-lowering drugs at T4 and T5, compared to 17%–40% in the general population within similar age groups and time periods.<sup>50</sup>

We observed different changes in free T<sub>3</sub> between cases and controls where cases generally had increased pre-diagnostic and decreased post-diagnostic concentrations. Free T<sub>3</sub> was positively associated with T2DM in men and women at T3, whereas free T<sub>4</sub> was inversely associated with T2DM in women at T3. This both agrees and disagrees with a recent meta-analysis including 12 prospective studies<sup>52</sup> that demonstrated positive associations between

TSH concentrations and T2DM, and inverse associations between free  $T_3$  and free  $T_4$  with T2DM. We did not observe any significant associations between TSH and T2DM, possibly due to small sample size. Time of blood sampling before diagnosis as well as study design might explain the different study observations. Accordingly, we observed that concentrations of free  $T_3$  were similar between cases and controls at T1, with a notable increase in cases to T3, followed by a post-diagnostic decline. This observation is in line with the study by Jun et al.<sup>53</sup> where they observed an increased  $T_3$  concentration at baseline followed by a decline over time in cases. This highlights that repeated measurements are important especially due to the properties of thyroid hormone homeostasis regulated by feedback mechanisms.<sup>54,55</sup> Discrete alterations in thyroid hormones may not be detected by measurement from a single time point and the interrelationship between levels of TSH, free  $T_3$  and free  $T_4$  and their associations with T2DM can be dependent on timing of measurements. There are very few longitudinal studies with repeated measurements of thyroid hormones with which we can compare our results to, and to our knowledge, none have presented repeated free  $T_3$  measurements. Our observations may indicate an imbalance in thyroid homeostasis in T2DM cases, which may result in subclinical hyperthyroidism or hypothyroidism, and in turn, may affect insulin resistance and glucose concentrations.<sup>56</sup>

The main strength of this study is the nested case-control design with repeated measurements which allowed us to study pre- and post-diagnostic changes over 30 years, and produce prediction models for the same individuals at three different pre-diagnostic time points. Moreover, we had high-quality information for many clinical variables, possible confounding factors and a wide spectrum of relevant biomarkers. The design provided us with an important evolutionary overview of the biomarkers and how they relate to the progression of T2DM and beyond. Information on T2DM diagnosis was collected from local registries and laboratory data up until the last survey, and medical records were used to confirm that none of the controls had been diagnosed with T2DM.

After stratifying by sex, there were few observations at each time point among cases and controls, which limits the precision of our effect estimates. Due to a lack of serum, we were not able to analyse thyroid hormones at T2 nor glucose at T1; moreover, GGT was unavailable at T3 and T5, as was HbA<sub>1c</sub> at T1. Waist circumference was also not available at T1, and only available for ~68% of subjects at T2. However, even though waist circumference has a stronger association with T2DM than BMI, it has not been shown to provide more accurate risk predictions of T2DM.<sup>57</sup> We had smaller sample sizes at post-diagnostic time points, as the inclusion criteria required an available blood sample at all pre-diagnostic ones. The prediction models were developed in a study sample from a northern Norwegian population, thus, the relative contribution of each predictor may vary in other populations due to genetical, environmental and lifestyle variations. Accordingly, our prediction models should be validated in different populations to verify their generalizability, and cut-offs should be re-evaluated if necessary.<sup>19</sup>

## 5 | CONCLUSIONS

Already 15 years before diagnosis, there were clear differences in blood biomarker concentrations between T2DM cases and controls and several blood biomarkers were associated with type T2DM. Selected blood biomarkers (lipids, HbA<sub>1c</sub>, GGT) in combination with BMI, physical activity, elevated blood pressure, and family history of T2DM had excellent predictive ability 1–7 years before type 2 T2DM diagnosis and acceptable predictive ability up to 15 years before diagnosis.

### ACKNOWLEDGEMENTS

We would like to thank all the participants of the Tromsø Study for their willingness to participate in the surveys and to donate blood. We would also like to thank the staff at the Department of Laboratory Medicine at the University Hospital of North Norway, who contributed with the laboratory analyses; especially Arnt R. Hagen and Tom Sollid.

### CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

### AUTHOR CONTRIBUTIONS

**Giovanni Allaoui:** Data curation (lead); Formal analysis (lead); Methodology (lead); Writing – original draft (lead); Writing – review & editing (equal). **Charlotta Rylander:** Conceptualization (equal); Funding acquisition (supporting); Methodology (supporting); Project administration (equal); Supervision (supporting); Writing – original draft (supporting); Writing – review & editing (equal). **Maria Averina:** Supervision (supporting); Writing – original draft (supporting); Writing – review & editing (supporting). **Tom Wilsgaard:** Formal analysis (supporting); Methodology (supporting); Supervision (supporting); Writing – review & editing (supporting). **Ole-Martin Fuskevåg:** Methodology (supporting); Supervision (supporting); Writing – review & editing (supporting). **Vivian Berg:** Conceptualization (equal); Funding acquisition (lead); Methodology (supporting); Project administration (lead); Resources (lead); Supervision (lead); Writing – original draft (supporting); Writing – review & editing (equal).

### DATA AVAILABILITY STATEMENT

The data set used in present study was derived from the Tromsø Study. It is not publicly available, but may be accessed through an application to the Tromsø Study (<https://uit.no/research/tromsostudy>).

### ORCID

Vivian Berg  <https://orcid.org/0000-0001-5620-9901>

### REFERENCES

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet*. 2016;387(10027):1513–1530. doi:10.1016/s0140-6736(16)00618-8

2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol*. 2018;14(2):88-98. doi:10.1038/nrendo.2017.151
3. Wannamethee SG, Papacosta O, Whincup PH, et al. The potential for a two-stage diabetes risk algorithm combining non-laboratory-based scores with subsequent routine non-fasting blood tests: results from prospective studies in older men and women. *Diabet Med*. 2011;28(1):23-30. doi:10.1111/j.1464-5491.2010.03171.x
4. Abbasi A, Sahlqvist AS, Lotta L, et al. A systematic review of biomarkers and risk of incident type 2 diabetes: an overview of epidemiological, prediction and aetiological research literature. *PLoS One*. 2016;11(10):e0163721. doi:10.1371/journal.pone.0163721
5. André P, Balkau B, Born C, Charles MA, Eschwège E. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. *Diabetologia*. 2006;49(11):2599-2603. doi:10.1007/s00125-006-0418-x
6. Joseph J, Svartberg J, Njølstad I, Schirmer H. Incidence of and risk factors for type-2 diabetes in a general population: the Tromsø study. *Scand J Public Health*. 2010;38(7):768-775. doi:10.1177/1403494810380299
7. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. *N Engl J Med*. 2008;359(21):2220-2232. doi:10.1056/NEJMoa0801869
8. Chaker L, Ligthart S, Korevaar TI, et al. Thyroid function and risk of type 2 diabetes: a population-based prospective cohort study. *BMC Med* 2016;14(1):150. doi:10.1186/s12916-016-0693-4
9. Gu Y, Li H, Bao X, et al. The relationship between thyroid function and the prevalence of type 2 diabetes mellitus in euthyroid subjects. *J Clin Endocrinol Metab*. 2017;102(2):434-442. doi:10.1210/jc.2016-2965
10. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. *Lancet*. 2009;373(9682):2215-2221. doi:10.1016/s0140-6736(09)60619-x
11. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *Lancet*. 2014;383(9922):1068-1083. doi:10.1016/s0140-6736(13)62154-6
12. Petersen KF, Shulman GI. Etiology of insulin resistance. *Am J Med*. 2006;119(5 Suppl 1):S10-S16. doi:10.1016/j.amjmed.2006.01.009
13. Haslam DW, James WP. Obesity. *Lancet*. 2005;366(9492):1197-1209. doi:10.1016/s0140-6736(05)67483-1
14. Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents and young adults. *Lancet Diabetes Endocrinol*. 2018;6(1):69-80. doi:10.1016/s2213-8587(17)30186-9
15. Sun Y, Gao H-Y, Fan Z-Y, He Y, Yan Y-X. Metabolomics signatures in type 2 diabetes: a systematic review and integrative analysis. *J Clin Endocrinol Metab*. 2019;105(4):1000-1008. doi:10.1210/clinem/dgz240
16. World Health Organization. *Global Report on Diabetes*. World Health Organization; 2016.
17. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. *Lancet*. 2011;378(9786):169-181. doi:10.1016/s0140-6736(11)60614-4
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010;S62-S69. doi:10.2337/dc10-S062
19. Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. *Epidemiol Rev*. 2011;33(1):46-62. doi:10.1093/epirev/mxq019
20. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham offspring study. *Arch Intern Med*. 2007;167(10):1068-1074. doi:10.1001/archinte.167.10.1068
21. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. *Diabetes Care*. 2003;26(3):725-731. doi:10.2337/diacare.26.3.725
22. Rathmann W, Kowall B, Heier M, et al. Prediction models for incident type 2 diabetes mellitus in the older population: KORA S4/F4 cohort study. *Diabet Med*. 2010;27(10):1116-1163. doi:10.1111/j.1464-5491.2010.03065.x
23. Herder C, Kowall B, Tabak AG, Rathmann W. The potential of novel biomarkers to improve risk prediction of type 2 diabetes. *Diabetologia*. 2014;57(1):16-29. doi:10.1007/s00125-013-3061-3
24. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. Cohort profile: The Tromsø study. *Int J Epidemiol*. 2011;41(4):961-967. doi:10.1093/ije/dyr049
25. UiT. The Tromsø study. 2020. <https://uit.no/research/tromsostudy> Accessed first of April, 2020
26. The Committee on Enzymes of Scandinavian Society for Clinical Physiology. Recommended method for the determination of  $\gamma$ -glutamyltransferase in blood. *Scand J Clin Lab Invest*. 1976;36(2):119-125. doi:10.1080/00365517609055236
27. Norwegian Accreditation. Accreditation scope for TEST 209: Universitetssykehuset Nord Norge HF, Laboratoriemedisin UNN. 2020. <https://www.akkrediter.no/en/akkrediterede-organisasjoner/akkrediteringsomfang/?AkkId=577> Accessed September 23, 2020.
28. Labquality. EQAS External quality assessment schemes. 2020. <https://www.labquality.fi/en/external-quality-assessment> Accessed September 23, 2020.
29. Phillips DL, Pirkle JL, Burse VW, Bernert JT Jr, Henderson LO, Needham LL. Chlorinated hydrocarbon levels in human serum: effects of fasting and feeding. *Arch Environ Contam Toxicol*. Jul-aug. 1989;18(4):495-500. doi:10.1007/bf01055015
30. Alberti KG, Zimmet P, Shaw J. International diabetes federation: a consensus on type 2 diabetes prevention. *Diabet Med*. 2007;24(5):451-463. doi:10.1111/j.1464-5491.2007.02157.x
31. Lindberg M, Garmo G, Hardang I, Monsen Bjørke A-L. Nasjonal brukerhåndbok i Medisinsk Biokjemi. 2020. <http://brukerhandboken.no/index.php> Accessed 9 December 2020.
32. Hosmer DW Jr, Lemeshow S, Sturdivant RX. Assessing the fit of the model. In: Hosmer DW, Lemeshow S, Sturdivant RX eds. *Applied Logistic Regression*. Third ed. John Wiley & Sons, Inc.; 2013:153-225.
33. Shi L, Brunius C, Lehtonen M, et al. Plasma metabolites associated with type 2 diabetes in a Swedish population: a case-control study nested in a prospective cohort. *Diabetologia*. 2018;61(4):849-861. doi:10.1007/s00125-017-4521-y
34. Schulze MB, Weikert C, Pischon T, et al. Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. *Diabetes Care*. 2009;32(11):2116-2119. doi:10.2337/dc09-0197
35. World Health O. *Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications : Report of a WHO Consultation. Part 1, Diagnosis and Classification of Diabetes Mellitus*. World Health Organization; 1999.
36. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). *Diabetes Care*. 2003;26(3):881-885. doi:10.2337/diacare.26.3.881
37. Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD. HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). *Diabetes Care*. 2001;24(3):465-471. doi:10.2337/diacare.24.3.465
38. Paprott R, Mensink GBM, Schulze MB, et al. Temporal changes in predicted risk of type 2 diabetes in Germany: findings from the German Health Interview and Examination Surveys 1997-1999 and



- 2008-2011. *BMJ Open*. 2017;7(7):e013058. doi:10.1136/bmjopen-2016-013058
39. Pimentel A, Carreiro AV, Ribeiro RT, Gamboa H. Screening diabetes mellitus 2 based on electronic health records using temporal features. *Health Informatics J*. 2018;24(2):194-205. doi:10.1177/1460458216663023
  40. Gurka MJ, Filipp SL, Pearson TA, DeBoer MD. Assessing baseline and temporal changes in cardiometabolic risk using metabolic syndrome severity and common risk scores. *J Am Heart Assoc*. 2018;7(16):e009754. doi:10.1161/jaha.118.009754
  41. Bernardini M, Morettini M, Romeo L, Frontoni E, Burattini L. Early temporal prediction of type 2 diabetes risk condition from a general practitioner electronic health record: a multiple instance boosting approach. *Artif Intell Med*. 2020;105:101847. doi:10.1016/j.artmed.2020.101847
  42. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. *Endocr Rev*. 2016;37(3):278-316. doi:10.1210/er.2015-1137
  43. Njølstad I, Arnesen E, Lund-Larsen PG. Sex differences in risk factors for clinical diabetes mellitus in a general population: a 12-year follow-up of the Finnmark Study. *Am J Epidemiol*. 1998;147(1):49-58. doi:10.1093/oxfordjournals.aje.a009366
  44. International Expert C. International expert committee report on the role of the a1c assay in the diagnosis of diabetes. *Diabetes Care*. 2009;32(7):1327-1334. doi:10.2337/dc09-9033
  45. Heianza Y, Arase Y, Fujihara K, et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon Hospital Health Management Center Study 7 (TOPICS 7). *Diabetes Care*. 2012;35(5):1050-1052. doi:10.2337/dc11-1793
  46. Kuwahara K, Honda T, Nakagawa T, Yamamoto S, Hayashi T, Mizoue T. Body mass index trajectory patterns and changes in visceral fat and glucose metabolism before the onset of type 2 diabetes. *Sci Rep*. 2017;7:43521. doi:10.1038/srep43521
  47. Hulsegge G, Spijkerman AMW, van der Schouw YT, et al. Trajectories of metabolic risk factors and biochemical markers prior to the onset of type 2 diabetes: the population-based longitudinal Doetinchem study. *Nutr Diabetes*. 2017;7(5):e270. doi:10.1038/nutd.2017.23
  48. Schneider ALC, Lazo M, Ndumele CE, et al. Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) study. *Diabet Med*. 2013;30(8):926-933. doi:10.1111/dme.12187
  49. Lee D-H, Blomhoff R, Jacobs DR. Reviews serum gamma glutamyltransferase a marker of oxidative stress? *Free Radical Res*. 2004;38(6):535-539. doi:10.1080/10715760410001694026
  50. Hopstock LA, Bønaa KH, Eggen AE, et al. Longitudinal and secular trends in total cholesterol levels and impact of lipid-lowering drug use among Norwegian women and men born in 1905-1977 in the population-based Tromsø Study 1979-2016. *BMJ Open*. 2017;7(8):e015001. doi:10.1136/bmjopen-2016-015001
  51. Ford ES, Li C, Sniderman A. Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008. *Cardiovasc Diabetol*. 2013;12(1):2005-2008. doi:10.1186/1475-2840-12-26
  52. Rong F, Dai H, Wu Y, et al. Association between thyroid dysfunction and type 2 diabetes: a meta-analysis of prospective observational studies. *BMC Med*. 2021;19(1):257. doi:10.1186/s12916-021-02121-2
  53. Jun JE, Jee JH, Bae JC, et al. Association between changes in thyroid hormones and incident type 2 diabetes: a seven-year longitudinal study. *Thyroid*. 2017;27(1):29-38. doi:10.1089/thy.2016.0171
  54. van der Spoel E, Roelfsema F, van Heemst D. Within-person variation in serum thyrotropin concentrations: main sources, potential underlying biological mechanisms, and clinical implications. review. *Front Endocrinol (Lausanne)*. 2021;12:619568. doi:10.3389/fendo.2021.619568
  55. Feldt-Rasmussen U, Hyltoft Petersen P, Blaabjerg O, Hørder M. Long-term variability in serum thyroglobulin and thyroid related hormones in healthy subjects. *Acta Endocrinol (Copenh)*. 1980;95(3):328-334. doi:10.1530/acta.0.0950328
  56. Jennings RE, Hanley NA. Endocrine Disorders that Cause Diabetes. In: Holt R, Cockram C, Flyvbjerg A, Goldstein B, eds. *Textbook of Diabetes*. 5th ed. John Wiley & Sons, Ltd; 2017:272-290.
  57. Lee CMY, Woodward M, Pandeya N, et al. Comparison of relationships between four common anthropometric measures and incident diabetes. *Diabetes Res Clin Pract*. 2017;132:36-44. doi:10.1016/j.diabres.2017.07.022

## SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

**How to cite this article:** Allaoui G, Rylander C, Averina M, Wilsgaard T, Fuskevåg O-M, Berg V. Longitudinal changes in blood biomarkers and their ability to predict type 2 diabetes mellitus—The Tromsø study. *Endocrinol Diab Metab*. 2022;5:e00325. doi:[10.1002/edm2.325](https://doi.org/10.1002/edm2.325)